质子放疗治疗IDH突变型WHO 2级和3级胶质瘤的安全性与疗效分析
分析194例IDH突变型WHO 2级(128例)和3级(66例)胶质瘤患者2010至2020年接受质子束放疗的安全性与疗效,中位随访5.1年。2级5年总生存率85%,3级67%;总体放射性对比增强(RICE)风险25%,2级29% vs 3级17%(p=0.13),RICE风险随年龄增长而升高(p=0.017)。
要点
- 质子束放疗后WHO 2级胶质瘤5年总生存率85%,3级为67%。
- 总体RICE风险25%,WHO 2级29% vs 3级17%,差异未达统计学显著(p=0.13)。
- RICE风险随年龄增长而升高(p=0.017),不依赖于肿瘤特征。
核心结论
- 这些数据表明质子束放疗对IDH突变型WHO 2级和3级胶质瘤有效。
- RICE风险随WHO分级不同而异,在年龄较大的IDH突变型WHO 2级和3级胶质瘤患者中更高。
研究设计与样本
- 分析194例诊断为IDH突变型WHO 2级(n=128)和WHO 3级(n=66)胶质瘤患者,2010年至2020年接受质子束放疗。
- 进行系列临床和影像学随访,中位随访5.1年。
主要发现
- WHO 2级中61%为星形细胞瘤、39%为少突胶质细胞瘤;WHO 3级中55%为星形细胞瘤、45%为少突胶质细胞瘤。
- IDH突变型胶质瘤中位剂量:WHO 2级为54 Gy(RBE)[范围50.4-60 Gy(RBE)],WHO 3级为60 Gy(RBE)[范围54-60 Gy(RBE)]。
- 5年总生存率:WHO 2级患者为85%,WHO 3级患者为67%。
- 总体RICE风险为25%,WHO 2级患者为29% vs WHO 3级患者为17%(p=0.13)。
- RICE风险随年龄增长而升高(p=0.017),不依赖于肿瘤特征。
关键数值与推荐
- 总体RICE在有症状的患者中占31%,对应CTCAE分级:1级80%、2级7%、3级13%、3级以上0%。
- 总体需要针对RICE治疗的比例为35%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Proton beam radiotherapy (PRT) has been demonstrated to improve neurocognitive sequelae particularly. Nevertheless, following PRT, increased rates of radiation-induced contrast enhancements (RICE) are feared. How safe and effective is PRT for IDH-mutated glioma WHO grade 2 and 3? METHODS: We analyzed 194 patients diagnosed with IDH-mutated WHO grade 2 (n = 128) and WHO grade 3 (n = 66) glioma who were treated with PRT from 2010 to 2020. Serial clinical and imaging follow-up was performed for a median of 5.1 years. RESULTS: For WHO grade 2, 61% were astrocytoma and 39% oligodendroglioma while for WHO grade 3, 55% were astrocytoma and 45% oligodendroglioma. Median dose for IDH-mutated glioma was 54 Gy(RBE) [range 50.4-60 Gy(RBE)] for WHO grade 2 and 60 Gy(RBE) [range 54-60 Gy(RBE)] for WHO grade 3. Five year overall survival was 85% in patients with WHO grade 2 and 67% in patients with WHO grade 3 tumors. Overall RICE risk was 25%, being higher in patients with WHO grade 2 (29%) versus in patients with WHO grade 3 (17%, p = 0.13). RICE risk increased independent of tumor characteristics with older age (p = 0.017). Overall RICE was symptomatic in 31% of patients with corresponding CTCAE grades as follows: 80% grade 1, 7% grade 2, 13% grade 3, and 0% grade 3 + . Overall need for RICE-directed therapy was 35%. CONCLUSION: These data demonstrate the effectiveness of PRT for IDH-mutated glioma WHO grade 2 and 3. The RICE risk differs with WHO grading and is higher in older patients with IDH-mutated Glioma WHO grade 2 and 3.
引用
- Eichkorn T, Lischalk JW, Hörner-Rieber J, et al. Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3. J Neurooncol. 2023. PMID: 36598613. doi:10.1007/s11060-022-04217-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。